Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing